One R’s First Year
With the rapid growth and maturity of our research network, it’s hard to believe OneR launched just one year ago.
OneR is a site management organization created to facilitate research collaboration among our affiliated OneOncology practices. OneR identifies clinical trials of high-scientific merit that align with our practices’ patient populations, research interests and capabilities. OneR provides study start-up services, project management support and financial management services reducing administrative burden and start-up timelines for our member practices.
Our site growth
OneR launched with three practices and has added an additional six this year. We anticipate similar growth in 2022 as practices, committed clinical research excellence, see the value and support our service model delivers.
I’m inspired by our practices’ commitment to ensuring their patients have access to the most promising new therapies. OneR is committed to support their efforts with resources and services to ensure the successful conduct of our trials and assist with the growth and development of their research programs.
With our partner practices, we’re building a community that supports each other’s research programs. Leaders from each practice meet monthly to discuss active and pending studies and to share best practices. This forum allows us the opportunity to discuss issues and challenges as well as introduce or get feedback on new technology and services. Running a community-based clinical research program can be very challenging, so it’s important that we support each other sharing tips, tools and encouragement.
We are extremely grateful for the overwhelming response from our sponsor partners. OneR successfully launched two clinical trials this year (during a pandemic) and have committed to an additional nine studies that are currently in study start up.
We’ve seen robust enrollment in our first two trials which are for patients with specific molecular alterations. Working with our partners at Foundation Medicine (FMI) and Flatiron Health, we identify potential study patients based on their comprehensive genomic profiling (CGP) testing and pre-screen them for our active studies. Our precision medicine colleagues assist these efforts by reviewing the FMI reports and making recommendations for clinical trials during our weekly precision tumor board meetings.
Over the next several years, OneR will continue to deliver practices trials for molecularly targeted therapies, but we’ll expand our portfolio to include trials in new combinations with immunotherapies and other promising therapeutics that have different mechanisms of action.
At 1, OneR has much to celebrate – robust site growth, complex trials launched, a growing roster of experienced research talent at the helm. We look forward to continued practice growth and delivering new and innovative trials to practices and the patients they serve.